|

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

RECRUITINGSponsored by Xiangya Hospital of Central South University
Actively Recruiting
SponsorXiangya Hospital of Central South University
Started2026-05-10
Est. completion2030-12-31
View on ClinicalTrials.gov →

NCT07608003

Summary

A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.

Eligibility

Inclusion Criteria:

* Patients with diffuse gliomas were pathologically and molecularly diagnosed.
* The clinical case data of all patients were complete.
* Patients underwent preoperative MRI examination.

Exclusion Criteria:

* The tumor is not located in the intracranial midline.
* Cases in which MRI were incomplete or with significant noise and artifacts.

Conditions7

CancerGlioma : Oligodendroglioma or AstrocytomaGlioma Glioblastoma MultiformeGlioma of BrainstemGlioma, Diffuse Midline, H3K27M-mutantGliomasGliomas Harboring IDH1 and/or IDH2 Mutations

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.